SIM0718 Treatment of Asthma Clinical Study

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SIM0718 in Adults and Adolescents With Asthma

Phase III clinical study of SIM0718 asthma

Study Overview

• Status: Recruiting
• Conditions: Asthma; Eosinophilic
• Intervention / Treatment: Drug: SIM0718 injection of placebo; Drug: SIM0718 injection

Detailed Description

A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III clinical study evaluating the efficacy and safety of SIM0718 in adults and adolescents with asthma

• Study Type: Interventional
• Enrollment (Estimated): 418
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Wei Wang
• Study Contact Backup: Name: Yi Wang; Phone Number: +8615805160455; Email: wangyi4@simcere.com

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100000
      • Recruiting
      • China Japan Friendship Hospital
      • Contact: Ting yang, doctor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 12 to 75 years, weight ≥ 40 kg, diagnosed with asthma for at least 12 months；
• Currently receiving medium- to high-dose inhaled corticosteroids (ICS) in combination with 1 or 2 control medications and have been on a stable dose for at least 28 days prior to randomization；
• Pre-bronchodilator (trough) FEV1 ≤ 80% of predicted normal for adults and ≤90% of predicted normal for adolescents ；
• Positive bronchodilator response within 12 months prior to randomization or during the screening period;
• Asthma Control Questionnaire (ACQ-5) score ≥ 1.5;
• At least one severe asthma exacerbation within 12 months prior to the screening visit and no occurrence within 28 days prior to randomization;
• Based on the investigator judgment, the subject demonstrates acceptable inhaler, peak flow meter, and spirometry techniques;
• Compliance with usual asthma controller use ≥ 80% based on the patient diary in 7 days prior to dosing;
• Voluntarily participate in this clinical study and sign the informed consent form and be able to comply with the clinical visit schedule and study-related procedures;
• Female subjects of childbearing potential who are sexually active with non-sterilized male partners, male subjects, and their female partners of childbearing potential agree to use adequate and effective contraception throughout the study;

Exclusion Criteria:

• Current respiratory disease that may impair lung function as judged by the investigator;
• Diagnosis of helminth parasitic infection within 24 weeks prior to randomization and who have not received or have not responded to standard therapy;
• Within 28 days prior to randomization, with acute or chronic infection; or have a severe viral infection;
• Has a known or suspected history of immunosuppression or frequent, recurrent, or long-term infection;
• History of active tuberculosis; or untreated latent tuberculosis or tuberculosis not receiving standard treatment, unless the investigator judges that the patient has been adequately treated;
• People with hepatitis B, hepatitis C, or HIV infection;
• History of malignancy;
• Major surgery within 8 weeks prior to signing the informed;
• Bronchial thermoplasty within 12 months prior to randomization;
• Treatment of systemic glucocorticoid during 4 weeks prior to signing informed to randomization;
• Previous use or ongoing use of systemic immunosuppressants or biologics for the treatment of autoimmune or inflammatory diseases in 8 weeks or 5 half-lives prior to randomization;
• Within 16 weeks or 5 half-lives prior to randomization, received a biologic agent with the same therapeutic purpose;
• Participated in an interventional clinical trial of any drug or medical device within 3 months or 5 half-lives prior to randomization;
• Poor response to or intolerance to prior anti-IL-4Rα antibody therapy;
• Within 3 months prior to randomization, received specific immunotherapy；
• Receipt of intravenous human immunoglobulin (IVIG) or blood products within 30 days prior to randomization;
• Vaccination with live(attenuated) vaccine within 30 days prior to randomization or plan to receive live (attenuated) vaccine during the study;
• Are using concomitant medications or treatments that are prohibited in the protocol;
• The following laboratory abnormalities occurred during the screening period: eosinophils≥1500 cells/mm3 or 1.5×109/L; Platelets≤80,000 cells/mm3 or 80×109/L; phosphocreatine kinase (CPK) ≥5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) ≥3-fold ULN; aspartate aminotransferase (AST)≥ 3-fold ULN; Bilirubin ≥ 2x ULN;
• History of alcohol abuse or drug abuse within 12 months prior to randomization;
• Current smokers, or those who have been smoking in recent 6 months, or former smokers who have not been smoking for 6 months with a smoking history of ≥10 pack years;
• Allergy to L-histidine, trehalose, or Tween 80, or history of systemic hypersensitivity to any biologic products;
• Females of childbearing potential have a positive pregnancy test result during the screening period; Females planning to become pregnant or breastfeeding;
• Any clinically significant examination abnormality or serious and/or uncontrolled disease that, in the opinion of the investigator, may affect the subject safety, or affect the evaluation of efficacy, or preclude the subject completion of the entire study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: SIM0718 injection of placebo; Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks. Duration of medication: 52 weeks
Experimental: SIM0718 injection	Drug: SIM0718 injection; Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks. Duration of medication: 52 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized rate of severe asthma exacerbation events	Annualized rate of severe asthma exacerbation events within 52 weeks	52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in forced expiratory volume in the first second before bronchodilator use	Change from baseline in forced expiratory volume in the first second before within 12 weeks	12 weeks
Change from baseline in Forced Vital Capacity (FVC)	Change from baseline in Forced Vital Capacity (FVC) of during the 52-week treatment period	During the 52-week treatment period
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second	Change from baseline in pre-bronchodilator forced expiratory volume in 1 second of during the 52-week treatment period	During the 52-week treatment period
Change from baseline in Peak Expiratory Flow (PEF)	Change from baseline in Peak Expiratory Flow (PEF) of during the 52-week treatment period	During the 52-week treatment period
Time from baseline to the first severe asthma exacerbation event, proportion of subjects with ≥ 1 severe asthma exacerbation	subjects with ≥ 1 severe asthma exacerbation of during the 52-week treatment period	During the 52-week treatment period
Annualized rate of "loss of asthma control" events, time from baseline to "loss of asthma control"event	Annualized rate of "loss of asthma control" events, time from baseline to "loss of asthma control"event of during the 52-week treatment period	During the 52-week treatment period
Change from baseline in annualized rate of hospitalization or emergency department visits, utilization of medical resources	Change from baseline in annualized rate of hospitalization or emergency department visits, utilization of medical resources of during the 52-week treatment period	During the 52-week treatment period
Change from baseline in ASTHMA CONTROL QUESTIONNAIRE(ACQ-5) score	Change from baseline in ASTHMA CONTROL QUESTIONNAIRE(ACQ-5) score (5 questions, 0-6 score, higher score indicated lower asthma control) of during the 52-week treatment period	During the 52-week treatment period
Asthma symptom score	Asthma symptom score (0-4 score, higher score indicated worse asthma symptom) during the 52-week treatment period	During the 52-week treatment period
Use of rescue medication	Use of rescue medication of during the 52-week treatment period	During the 52-week treatment period
Number of days of awakenings due to asthma and number of awakenings due to asthma	Number of days of awakenings due to asthma and number of awakenings due to asthma of during the 52-week treatment period	During the 52-week treatment period
Change from baseline in standardized asthma quality of life questionnaire score ASTHMA QUALITY OF LIFE QUESTIONNAIRES(AQLQ(S))	Change from baseline in standardized asthma quality of life questionnaire score(AQLQ(S)) (32 questions, 1-7 score, higher scores indicate better quality of life) of during the 52-week treatment period	During the 52-week treatment period
Adverse events	Adverse events during 64 week study period	during the 64 week study period
Vital signs	Vital signs during 64 week study period	during the 64 week study period
Electrocardiograph (12-ECG)	Electrocardiograph (12-ECG) during 64 week study period	during the 64 week study period
Laboratory tests	Laboratory tests during 64-week study period. Lab tests include hematology, biochemistry	during the 64 week study period
SIM0718 blood concentration	SIM0718 blood concentration of during the 52-week treatment period	During the 52-week treatment period
Positive rate and titer of anti-drug antibodies, positive rate of neutralizing antibodies	Positive rate and titer of anti-drug antibodies, positive rate of neutralizing antibodies of 64 weeks during the study	64 weeks during the study

Collaborators and Investigators

• Sponsor: Simcere Pharmaceutical Co., Ltd
• Investigators: Study Director: L I hong zhuang, Simcere Pharmaceutical Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): June 23, 2024
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): September 30, 2027

Study Registration Dates

• First Submitted: June 24, 2024
• First Submitted That Met QC Criteria: June 28, 2024
• First Posted (Actual): July 5, 2024

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: March 29, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Hypereosinophilic Syndrome; Eosinophilia; Leukocyte Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Pulmonary Eosinophilia
• Other Study ID Numbers: SIM0718-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No